| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, B-Cell | 6 | 2023 | 109 | 3.080 |
Why?
|
| Hodgkin Disease | 12 | 2024 | 170 | 3.000 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 13 | 2025 | 187 | 2.880 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 5 | 2023 | 31 | 1.950 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2024 | 429 | 1.780 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2024 | 164 | 1.190 |
Why?
|
| Biomarkers, Tumor | 8 | 2019 | 1576 | 1.170 |
Why?
|
| Lymphoproliferative Disorders | 4 | 2023 | 109 | 1.070 |
Why?
|
| Mutation | 8 | 2024 | 4204 | 1.070 |
Why?
|
| Bone Marrow | 4 | 2022 | 445 | 1.030 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2017 | 22 | 0.970 |
Why?
|
| Mediastinal Neoplasms | 2 | 2022 | 45 | 0.940 |
Why?
|
| 5-Methylcytosine | 2 | 2022 | 117 | 0.860 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2023 | 209 | 0.810 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2022 | 30 | 0.780 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2022 | 45 | 0.780 |
Why?
|
| Epstein-Barr Virus Infections | 5 | 2019 | 55 | 0.760 |
Why?
|
| Lymphoma, T-Cell | 1 | 2022 | 59 | 0.740 |
Why?
|
| Lymphoma, Mantle-Cell | 4 | 2021 | 39 | 0.730 |
Why?
|
| Humans | 74 | 2025 | 92337 | 0.720 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2020 | 6 | 0.710 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2017 | 174 | 0.680 |
Why?
|
| STAT6 Transcription Factor | 1 | 2019 | 28 | 0.660 |
Why?
|
| Leukemia | 1 | 2022 | 321 | 0.660 |
Why?
|
| Bone Marrow Cells | 3 | 2019 | 264 | 0.630 |
Why?
|
| Prognosis | 11 | 2024 | 3872 | 0.600 |
Why?
|
| Reed-Sternberg Cells | 3 | 2024 | 4 | 0.580 |
Why?
|
| Middle Aged | 33 | 2025 | 27030 | 0.580 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 268 | 0.560 |
Why?
|
| T-Lymphocytes | 3 | 2020 | 1277 | 0.540 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 111 | 0.530 |
Why?
|
| Erythrocyte Aggregation | 1 | 2016 | 4 | 0.510 |
Why?
|
| Infectious Mononucleosis | 1 | 2016 | 6 | 0.510 |
Why?
|
| Aged | 28 | 2024 | 19943 | 0.510 |
Why?
|
| Adenocarcinoma | 3 | 2008 | 1191 | 0.510 |
Why?
|
| Male | 39 | 2025 | 43925 | 0.510 |
Why?
|
| Diagnosis, Differential | 9 | 2019 | 1592 | 0.500 |
Why?
|
| Histiocytosis, Sinus | 2 | 2019 | 14 | 0.500 |
Why?
|
| Lymphocytes | 3 | 2023 | 476 | 0.500 |
Why?
|
| Adult | 28 | 2025 | 27532 | 0.480 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2019 | 419 | 0.470 |
Why?
|
| Female | 36 | 2025 | 47893 | 0.470 |
Why?
|
| Piperidines | 4 | 2021 | 164 | 0.460 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 460 | 0.440 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 6916 | 0.440 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2013 | 7 | 0.440 |
Why?
|
| CD11c Antigen | 1 | 2013 | 13 | 0.430 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2013 | 32 | 0.430 |
Why?
|
| Cytoplasmic Granules | 1 | 2013 | 99 | 0.420 |
Why?
|
| Herpesvirus 8, Human | 1 | 2013 | 11 | 0.420 |
Why?
|
| Sarcoma, Kaposi | 1 | 2013 | 18 | 0.420 |
Why?
|
| Antigens, CD | 2 | 2013 | 473 | 0.420 |
Why?
|
| Castleman Disease | 1 | 2013 | 14 | 0.420 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2013 | 18 | 0.420 |
Why?
|
| Prostatic Neoplasms | 4 | 2008 | 1771 | 0.410 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 52 | 0.410 |
Why?
|
| Neoplasm Staging | 7 | 2024 | 2035 | 0.400 |
Why?
|
| Down-Regulation | 2 | 2022 | 523 | 0.400 |
Why?
|
| Immunohistochemistry | 9 | 2022 | 1807 | 0.400 |
Why?
|
| B-Lymphocytes | 5 | 2023 | 754 | 0.390 |
Why?
|
| Monocytes | 1 | 2013 | 223 | 0.390 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2011 | 4 | 0.380 |
Why?
|
| Integrin alpha Chains | 1 | 2011 | 16 | 0.380 |
Why?
|
| Lewis X Antigen | 1 | 2011 | 9 | 0.370 |
Why?
|
| Fucosyltransferases | 1 | 2011 | 9 | 0.360 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2011 | 186 | 0.360 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2011 | 16 | 0.360 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2023 | 183 | 0.360 |
Why?
|
| Sclerosis | 1 | 2010 | 29 | 0.350 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2010 | 23 | 0.350 |
Why?
|
| Dura Mater | 1 | 2010 | 50 | 0.340 |
Why?
|
| Autoimmune Lymphoproliferative Syndrome | 1 | 2010 | 2 | 0.340 |
Why?
|
| Histiocytic Sarcoma | 1 | 2010 | 8 | 0.340 |
Why?
|
| Image Cytometry | 2 | 2007 | 12 | 0.340 |
Why?
|
| Meningeal Neoplasms | 1 | 2010 | 71 | 0.330 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 407 | 0.330 |
Why?
|
| Flow Cytometry | 5 | 2024 | 704 | 0.320 |
Why?
|
| Neoplasms | 2 | 2020 | 3117 | 0.320 |
Why?
|
| Pyrimidines | 3 | 2018 | 378 | 0.310 |
Why?
|
| DNA, Neoplasm | 4 | 2013 | 269 | 0.300 |
Why?
|
| Immunophenotyping | 4 | 2019 | 222 | 0.300 |
Why?
|
| Aneuploidy | 2 | 2007 | 58 | 0.300 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2023 | 139 | 0.300 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 355 | 0.290 |
Why?
|
| Neoplasm Proteins | 3 | 2019 | 547 | 0.290 |
Why?
|
| Melanoma | 2 | 2024 | 482 | 0.290 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2023 | 622 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 1398 | 0.280 |
Why?
|
| Adolescent | 11 | 2025 | 9504 | 0.270 |
Why?
|
| Lymph Nodes | 3 | 2020 | 552 | 0.270 |
Why?
|
| Skin Neoplasms | 2 | 2024 | 606 | 0.270 |
Why?
|
| Pyrazoles | 2 | 2018 | 153 | 0.260 |
Why?
|
| Ploidies | 1 | 2006 | 41 | 0.260 |
Why?
|
| Phenotype | 2 | 2023 | 2498 | 0.250 |
Why?
|
| Logistic Models | 2 | 2007 | 1239 | 0.250 |
Why?
|
| Tumor Microenvironment | 3 | 2025 | 520 | 0.250 |
Why?
|
| Pathology, Clinical | 1 | 2006 | 36 | 0.250 |
Why?
|
| Flavonoids | 1 | 2006 | 85 | 0.250 |
Why?
|
| Adenine | 3 | 2021 | 89 | 0.240 |
Why?
|
| Plasma Cells | 2 | 2019 | 86 | 0.240 |
Why?
|
| Observer Variation | 2 | 2007 | 612 | 0.240 |
Why?
|
| Young Adult | 12 | 2025 | 6624 | 0.240 |
Why?
|
| Statistics as Topic | 1 | 2006 | 234 | 0.240 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2024 | 462 | 0.240 |
Why?
|
| Antibodies, Bispecific | 1 | 2025 | 31 | 0.240 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 2368 | 0.240 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2025 | 37 | 0.230 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2024 | 23 | 0.230 |
Why?
|
| Biopsy | 2 | 2019 | 1194 | 0.230 |
Why?
|
| Oxidative Phosphorylation | 1 | 2024 | 63 | 0.220 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2024 | 80 | 0.220 |
Why?
|
| Biomarkers | 3 | 2023 | 1850 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2020 | 105 | 0.220 |
Why?
|
| Cystic Fibrosis | 1 | 2025 | 118 | 0.220 |
Why?
|
| Incidental Findings | 1 | 2024 | 98 | 0.220 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2023 | 5 | 0.210 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 403 | 0.210 |
Why?
|
| In Situ Hybridization | 4 | 2013 | 313 | 0.210 |
Why?
|
| Dermatitis | 1 | 2023 | 35 | 0.210 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2023 | 923 | 0.210 |
Why?
|
| Exanthema | 1 | 2023 | 41 | 0.200 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 56 | 0.200 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 698 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2024 | 139 | 0.190 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 245 | 0.190 |
Why?
|
| Apoptosis | 2 | 2023 | 1743 | 0.190 |
Why?
|
| Cyclin D1 | 2 | 2016 | 84 | 0.190 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 1763 | 0.190 |
Why?
|
| Neoplasm, Residual | 2 | 2021 | 188 | 0.180 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 611 | 0.180 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 213 | 0.180 |
Why?
|
| Cell Nucleus | 3 | 2008 | 612 | 0.180 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 252 | 0.180 |
Why?
|
| Cell Proliferation | 2 | 2023 | 1720 | 0.180 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 286 | 0.180 |
Why?
|
| Cell Lineage | 1 | 2022 | 302 | 0.180 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 366 | 0.170 |
Why?
|
| Spleen | 2 | 2013 | 435 | 0.170 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2021 | 97 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2020 | 22 | 0.170 |
Why?
|
| Mitochondria | 1 | 2024 | 599 | 0.170 |
Why?
|
| Chromothripsis | 1 | 2020 | 8 | 0.170 |
Why?
|
| Lung Transplantation | 1 | 2025 | 350 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 2556 | 0.170 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2020 | 13 | 0.170 |
Why?
|
| Combined Modality Therapy | 4 | 2015 | 1733 | 0.170 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2019 | 4 | 0.170 |
Why?
|
| Mastitis | 1 | 2019 | 5 | 0.170 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2009 | 374 | 0.160 |
Why?
|
| Biopsy, Needle | 3 | 2012 | 229 | 0.160 |
Why?
|
| Genomic Instability | 1 | 2020 | 84 | 0.160 |
Why?
|
| Sezary Syndrome | 1 | 2019 | 12 | 0.160 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2019 | 48 | 0.160 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2019 | 30 | 0.160 |
Why?
|
| Mycosis Fungoides | 1 | 2019 | 30 | 0.160 |
Why?
|
| Ki-1 Antigen | 1 | 2019 | 19 | 0.160 |
Why?
|
| Breast Diseases | 1 | 2019 | 101 | 0.160 |
Why?
|
| Thymus Neoplasms | 1 | 2019 | 43 | 0.150 |
Why?
|
| Graft Rejection | 1 | 2025 | 1110 | 0.150 |
Why?
|
| Inflammation | 1 | 2025 | 1025 | 0.150 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 52 | 0.150 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 20 | 0.150 |
Why?
|
| Sulfonamides | 1 | 2021 | 328 | 0.150 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 83 | 0.150 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2018 | 47 | 0.150 |
Why?
|
| Treatment Outcome | 6 | 2024 | 8740 | 0.150 |
Why?
|
| Breast | 1 | 2019 | 289 | 0.140 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 538 | 0.140 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 180 | 0.140 |
Why?
|
| Muscle, Smooth | 2 | 2009 | 355 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2009 | 154 | 0.130 |
Why?
|
| CD5 Antigens | 1 | 2016 | 14 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2017 | 461 | 0.130 |
Why?
|
| Coombs Test | 1 | 2016 | 8 | 0.130 |
Why?
|
| Burkitt Lymphoma | 1 | 2015 | 33 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2019 | 358 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 307 | 0.120 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2023 | 43 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 283 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 1477 | 0.110 |
Why?
|
| Chediak-Higashi Syndrome | 1 | 2013 | 2 | 0.110 |
Why?
|
| Leukocytosis | 1 | 2013 | 15 | 0.110 |
Why?
|
| Blood Cell Count | 1 | 2013 | 80 | 0.110 |
Why?
|
| HLA-DR Antigens | 1 | 2013 | 59 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2013 | 2978 | 0.110 |
Why?
|
| Data Mining | 1 | 2013 | 44 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 923 | 0.100 |
Why?
|
| Survival Rate | 2 | 2019 | 1927 | 0.100 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2013 | 9 | 0.100 |
Why?
|
| Laser Capture Microdissection | 1 | 2013 | 20 | 0.100 |
Why?
|
| Carcinoma | 2 | 2024 | 438 | 0.100 |
Why?
|
| Cell Line, Tumor | 3 | 2023 | 2669 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 299 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 891 | 0.100 |
Why?
|
| Viral Load | 1 | 2013 | 148 | 0.100 |
Why?
|
| DNA, Viral | 1 | 2013 | 253 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2010 | 107 | 0.100 |
Why?
|
| Gene Rearrangement | 1 | 2013 | 176 | 0.100 |
Why?
|
| Pseudolymphoma | 1 | 2011 | 9 | 0.090 |
Why?
|
| Cell Separation | 1 | 2011 | 202 | 0.090 |
Why?
|
| Mice | 5 | 2024 | 12110 | 0.090 |
Why?
|
| Mucous Membrane | 2 | 2009 | 84 | 0.090 |
Why?
|
| Urothelium | 2 | 2009 | 65 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2025 | 9703 | 0.090 |
Why?
|
| Clone Cells | 1 | 2010 | 214 | 0.090 |
Why?
|
| Herpesvirus 4, Human | 1 | 2011 | 122 | 0.090 |
Why?
|
| Oral Ulcer | 1 | 2010 | 3 | 0.080 |
Why?
|
| Skin Diseases, Infectious | 1 | 2010 | 12 | 0.080 |
Why?
|
| Rituximab | 2 | 2023 | 123 | 0.080 |
Why?
|
| Recurrence | 3 | 2023 | 1180 | 0.080 |
Why?
|
| Skin Ulcer | 1 | 2010 | 25 | 0.080 |
Why?
|
| Piperazines | 1 | 2012 | 288 | 0.080 |
Why?
|
| fas Receptor | 1 | 2010 | 78 | 0.080 |
Why?
|
| Family Health | 1 | 2010 | 158 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2013 | 955 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2010 | 299 | 0.080 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 383 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 1 | 2010 | 289 | 0.080 |
Why?
|
| Myoepithelioma | 1 | 2008 | 10 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2010 | 153 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2010 | 288 | 0.070 |
Why?
|
| Parotid Neoplasms | 1 | 2008 | 16 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1902 | 0.070 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2008 | 34 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2009 | 132 | 0.070 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2007 | 6 | 0.070 |
Why?
|
| Karyotype | 2 | 2019 | 34 | 0.070 |
Why?
|
| Discriminant Analysis | 1 | 2007 | 66 | 0.070 |
Why?
|
| Cytoskeletal Proteins | 1 | 2009 | 227 | 0.070 |
Why?
|
| Sarcoma, Ewing | 1 | 2007 | 43 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2008 | 595 | 0.070 |
Why?
|
| Immune Tolerance | 1 | 2010 | 359 | 0.070 |
Why?
|
| Sarcoma, Synovial | 1 | 2007 | 21 | 0.070 |
Why?
|
| Germ-Line Mutation | 1 | 2010 | 358 | 0.070 |
Why?
|
| Vaginal Smears | 1 | 2007 | 70 | 0.070 |
Why?
|
| Histological Techniques | 1 | 2006 | 36 | 0.070 |
Why?
|
| Antibodies | 1 | 2009 | 351 | 0.070 |
Why?
|
| Genomics | 2 | 2025 | 806 | 0.070 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2007 | 34 | 0.070 |
Why?
|
| Photometry | 1 | 2006 | 14 | 0.070 |
Why?
|
| Cytogenetic Analysis | 1 | 2006 | 71 | 0.070 |
Why?
|
| Testicular Neoplasms | 1 | 2007 | 120 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2006 | 36 | 0.060 |
Why?
|
| Papillomaviridae | 1 | 2007 | 165 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2007 | 123 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2023 | 3508 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2006 | 54 | 0.060 |
Why?
|
| Retinoblastoma Protein | 1 | 2006 | 66 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2006 | 164 | 0.060 |
Why?
|
| Animals | 5 | 2024 | 28003 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 3775 | 0.060 |
Why?
|
| Urinary Bladder | 1 | 2007 | 250 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2006 | 476 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2007 | 341 | 0.060 |
Why?
|
| Antigens, CD19 | 1 | 2025 | 69 | 0.060 |
Why?
|
| Cytological Techniques | 1 | 2005 | 31 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 989 | 0.060 |
Why?
|
| Sentinel Lymph Node | 1 | 2024 | 21 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 598 | 0.060 |
Why?
|
| India | 1 | 2005 | 128 | 0.060 |
Why?
|
| Eosinophils | 1 | 2025 | 197 | 0.060 |
Why?
|
| Allografts | 1 | 2025 | 197 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2007 | 578 | 0.050 |
Why?
|
| ROC Curve | 1 | 2006 | 785 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2007 | 274 | 0.050 |
Why?
|
| Vincristine | 1 | 2023 | 109 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2023 | 56 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2007 | 434 | 0.050 |
Why?
|
| Neutrophils | 1 | 2025 | 323 | 0.050 |
Why?
|
| Prednisone | 1 | 2023 | 254 | 0.050 |
Why?
|
| Prostatectomy | 1 | 2006 | 479 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2007 | 680 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2024 | 351 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 304 | 0.050 |
Why?
|
| Lymphoma | 1 | 2024 | 267 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2023 | 296 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2023 | 4468 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2023 | 142 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 254 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 105 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2023 | 190 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 174 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2025 | 963 | 0.050 |
Why?
|
| Child | 1 | 2013 | 7334 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2024 | 455 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 333 | 0.040 |
Why?
|
| Emperipolesis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2021 | 119 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 1271 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 358 | 0.040 |
Why?
|
| Disease Progression | 2 | 2019 | 1503 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2020 | 108 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2020 | 61 | 0.040 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2019 | 16 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2007 | 2369 | 0.040 |
Why?
|
| Erythroid Cells | 1 | 2019 | 15 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 2019 | 36 | 0.040 |
Why?
|
| S100 Proteins | 1 | 2019 | 53 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2021 | 431 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 125 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2020 | 211 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 1052 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 241 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2019 | 106 | 0.040 |
Why?
|
| Tretinoin | 1 | 2019 | 131 | 0.040 |
Why?
|
| United States | 2 | 2024 | 7348 | 0.040 |
Why?
|
| Immediate-Early Proteins | 1 | 2020 | 164 | 0.040 |
Why?
|
| Benzodioxoles | 1 | 2018 | 14 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 2019 | 168 | 0.040 |
Why?
|
| Fibrosis | 1 | 2019 | 239 | 0.040 |
Why?
|
| Mortality | 1 | 2019 | 150 | 0.040 |
Why?
|
| Purines | 1 | 2018 | 97 | 0.040 |
Why?
|
| Histiocytes | 1 | 2017 | 23 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 2448 | 0.030 |
Why?
|
| World Health Organization | 2 | 2007 | 114 | 0.030 |
Why?
|
| Time Factors | 1 | 2006 | 5430 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2517 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 502 | 0.030 |
Why?
|
| src Homology Domains | 1 | 2016 | 46 | 0.030 |
Why?
|
| Infant | 1 | 2023 | 3218 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 1181 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2019 | 470 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 569 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 531 | 0.030 |
Why?
|
| Risk Factors | 1 | 2025 | 5704 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 1310 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 2013 | 127 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 498 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1511 | 0.020 |
Why?
|
| Pancytopenia | 1 | 2012 | 23 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2012 | 127 | 0.020 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2011 | 20 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 1071 | 0.020 |
Why?
|
| Developed Countries | 1 | 2011 | 25 | 0.020 |
Why?
|
| Benzamides | 1 | 2012 | 239 | 0.020 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2010 | 20 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 53 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2010 | 68 | 0.020 |
Why?
|
| Genes, Immunoglobulin | 1 | 2010 | 111 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2009 | 126 | 0.020 |
Why?
|
| Fractures, Compression | 1 | 2007 | 20 | 0.020 |
Why?
|
| Pathology | 1 | 2007 | 32 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2008 | 284 | 0.020 |
Why?
|
| Bone Screws | 1 | 2007 | 52 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2007 | 152 | 0.020 |
Why?
|
| Societies, Scientific | 1 | 2007 | 43 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2007 | 128 | 0.020 |
Why?
|
| Spinal Fractures | 1 | 2007 | 95 | 0.020 |
Why?
|
| Urology | 1 | 2007 | 125 | 0.020 |
Why?
|
| Aging | 1 | 2011 | 738 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 1905 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2007 | 288 | 0.010 |
Why?
|
| Spinal Fusion | 1 | 2007 | 237 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2007 | 601 | 0.010 |
Why?
|
| Prostate | 1 | 2006 | 413 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 2009 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 1079 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 3509 | 0.010 |
Why?
|